Regeneron Pharmaceuticals Inc.

814.99+6.68+0.83%Vol 336.64K1Y Perf 9.30%
Oct 4th, 2023 16:00 DELAYED
BID770.00 ASK825.00
Open809.16 Previous Close808.31
Pre-Market- After-Market814.99
 - -  - -%
Target Price
801.83 
Analyst Rating
Moderate Buy 1.65
Potential %
-1.61 
Finscreener Ranking
★★★★     52.93
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★+     58.27
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     71.31
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
81.89 
Earnings Rating
Strong Buy
Market Cap88.47B 
Earnings Date
2nd Nov 2023
Alpha0.01 Standard Deviation0.09
Beta0.19 

Today's Price Range

805.93816.70

52W Range

668.00847.50

5 Year PE Ratio Range

12.7070.20

Summary:

Neutral

Technical Indicators: Sell
Moving Averages: Neutral
Performance
1 Week
-2.91%
1 Month
-2.80%
3 Months
12.56%
6 Months
-1.68%
1 Year
9.30%
3 Years
43.11%
5 Years
106.18%
10 Years
161.93%

TickerPriceChg.Chg.%
REGN814.996.68000.83
AAPL173.661.26000.73
GOOG136.272.97002.23
MSFT318.965.56501.78
XOM111.50-4.3300-3.74
WFC38.970.30000.78
JNJ155.520.18000.12
FB196.640.99000.51
GE108.851.09001.01
JPM143.350.64000.45
Financial StrengthValueIndustryS&P 500US Markets
4.40
5.40
0.11
0.13
108.60
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
85.00
44.40
46.70
41.20
35.87
RevenueValueIndustryS&P 500US Markets
8.76B
81.79
29.79
23.16
Earnings HistoryEstimateReportedSurprise %
Q02 20238.488.793.66
Q01 20237.718.449.47
Q04 20228.1810.9633.99
Q03 20228.559.9816.73
Q02 20228.539.7714.54
Q01 20229.3711.4922.63
Q04 202118.4923.7228.29
Q03 20219.8115.3756.68
Earnings Per EndEstimateRevision %Trend
9/2023 QR9.582.02Positive
12/2023 QR9.024.16Positive
12/2023 FY35.421.81Positive
12/2024 FY36.340.36Positive
Next Report Date2nd Nov 2023
Estimated EPS Next Report9.55
Estimates Count9
EPS Growth Next 5 Years %9.50
Volume Overview
Volume336.64K
Shares Outstanding108.56K
Shares Float100.96M
Trades Count14.19K
Dollar Volume273.69M
Avg. Volume432.31K
Avg. Weekly Volume407.60K
Avg. Monthly Volume396.89K
Avg. Quarterly Volume492.44K

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock closed at 808.31 per share at the end of the most recent trading day (a -1.19% change compared to the prior day closing price) with a volume of 421.47K shares and market capitalization of 88.47B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 9123 people. Regeneron Pharmaceuticals Inc. CEO is Leonard S. Schleifer.

The one-year performance of Regeneron Pharmaceuticals Inc. stock is 9.3%, while year-to-date (YTD) performance is 12.03%. REGN stock has a five-year performance of 106.18%. Its 52-week range is between 668 and 847.5, which gives REGN stock a 52-week price range ratio of 81.89%

Regeneron Pharmaceuticals Inc. currently has a PE ratio of 15.50, a price-to-book (PB) ratio of 3.74, a price-to-sale (PS) ratio of 8.32, a price to cashflow ratio of 14.70, a PEG ratio of 1.63, a ROA of 22.50%, a ROC of 24.99% and a ROE of 29.79%. The company’s profit margin is 35.87%, its EBITDA margin is 46.70%, and its revenue ttm is $8.76 Billion , which makes it $81.79 revenue per share.

Of the last four earnings reports from Regeneron Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $9.55 for the next earnings report. Regeneron Pharmaceuticals Inc.’s next earnings report date is 02nd Nov 2023.

The consensus rating of Wall Street analysts for Regeneron Pharmaceuticals Inc. is Moderate Buy (1.65), with a target price of $801.83, which is -1.61% compared to the current price. The earnings rating for Regeneron Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Regeneron Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Regeneron Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.74, ATR14 : 13.85, CCI20 : -253.12, Chaikin Money Flow : -0.09, MACD : 2.70, Money Flow Index : 42.43, ROC : -1.83, RSI : 41.63, STOCH (14,3) : 21.00, STOCH RSI : 0.00, UO : 47.51, Williams %R : -79.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Regeneron Pharmaceuticals Inc. in the last 12-months were: Andrew J Murphy (Option Excercise at a value of $1 791 300), Andrew J Murphy (Sold 3 699 shares of value $2 692 066 ), Arthur Frederick Ryan (Sold 439 shares of value $336 484 ), Bonnie L. Bassler (Option Excercise at a value of $944 375), Bonnie L. Bassler (Sold 2 479 shares of value $1 979 501 ), Christopher R. Fenimore (Option Excercise at a value of $1 352 150), Christopher R. Fenimore (Sold 4 036 shares of value $3 148 938 ), Daniel P. Van Plew (Option Excercise at a value of $31 934 280), Daniel P. Van Plew (Sold 19 858 shares of value $14 746 520 ), Fenimore Christopher (Option Excercise at a value of $1 352 150), Fenimore Christopher (Sold 4 036 shares of value $3 148 938 ), George D. Yancopoulos (Sold 16 591 shares of value $13 289 279 ), Goldstein Joseph (Option Excercise at a value of $1 743 922), Goldstein Joseph (Sold 3 613 shares of value $2 890 400 ), Joseph J. Larosa (Option Excercise at a value of $2 704 300), Joseph L. Goldstein (Option Excercise at a value of $1 743 922), Joseph L. Goldstein (Sold 3 613 shares of value $2 890 400 ), Larosa Joseph (Option Excercise at a value of $2 704 300), Marion Mccourt (Option Excercise at a value of $3 203 156), Marion McCourt (Sold 9 364 shares of value $7 065 970 ), Michael S. Brown (Option Excercise at a value of $11 245 057), Michael S. Brown (Sold 22 818 shares of value $17 741 539 ), P. Roy Vagelos (Option Excercise at a value of $11 493 275), Poon Christine (Option Excercise at a value of $3 360 667), Poon Christine (Sold 12 280 shares of value $10 314 827 ), Robert E. Landry (Option Excercise at a value of $6 025 516), Robert E. Landry (Sold 4 251 shares of value $3 336 322 ), Ryan Arthur (Sold 196 shares of value $142 432 ), Stahl Neil (Sold 0 shares of value $-19 983 000 ), Stahl Neil (Sold 11 665 shares of value $9 810 082 ), Vagelos P. (Sold 0 shares of value $-11 493 275 ), Yancopoulos George (Sold 16 591 shares of value $13 289 279 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
16 (69.57 %)
15 (71.43 %)
14 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
6 (26.09 %)
5 (23.81 %)
6 (28.57 %)
Moderate Sell
1 (4.35 %)
1 (4.76 %)
1 (4.76 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.65
Moderate Buy
1.62
Moderate Buy
1.71

Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.

CEO: Leonard S. Schleifer

Telephone: +1 914 847-7000

Address: 777 Old Saw Mill River Road, Tarrytown 10591-6707, NY, US

Number of employees: 9 123

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

44%56%

Bearish Bullish

58%42%

Bearish Bullish

54%46%

 

News

Stocktwits